Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its stake in Puma Biotechnology, Inc. (NASDAQ:PBYIGet Rating) by 9.5% during the first quarter, HoldingsChannel reports. The firm owned 90,731 shares of the biopharmaceutical company’s stock after selling 9,484 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Puma Biotechnology were worth $261,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new position in Puma Biotechnology in the 1st quarter worth about $400,000. Los Angeles Capital Management LLC increased its stake in Puma Biotechnology by 5.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 123,970 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 6,289 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in Puma Biotechnology by 4.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 511,233 shares of the biopharmaceutical company’s stock worth $1,472,000 after acquiring an additional 19,951 shares during the period. Russell Investments Group Ltd. boosted its position in Puma Biotechnology by 78.2% during the 1st quarter. Russell Investments Group Ltd. now owns 172,732 shares of the biopharmaceutical company’s stock worth $497,000 after acquiring an additional 75,811 shares during the period. Finally, Prospera Financial Services Inc boosted its position in Puma Biotechnology by 65.6% during the 1st quarter. Prospera Financial Services Inc now owns 59,680 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 23,648 shares during the period. Hedge funds and other institutional investors own 62.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. StockNews.com upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Monday, August 8th. HC Wainwright decreased their price objective on Puma Biotechnology from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, August 5th.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $2.58 on Tuesday. The company has a current ratio of 2.01, a quick ratio of 1.89 and a debt-to-equity ratio of 4.95. Puma Biotechnology, Inc. has a 52-week low of $1.60 and a 52-week high of $7.73. The stock has a 50-day simple moving average of $3.09 and a 200-day simple moving average of $2.72.

Insider Activity

In related news, CEO Alan H. Auerbach sold 26,140 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $2.63, for a total value of $68,748.20. Following the completion of the sale, the chief executive officer now directly owns 6,317,952 shares in the company, valued at approximately $16,616,213.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Puma Biotechnology news, Director Michael Patrick Miller sold 25,000 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $3.55, for a total value of $88,750.00. Following the transaction, the director now directly owns 54,858 shares of the company’s stock, valued at approximately $194,745.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Alan H. Auerbach sold 26,140 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $2.63, for a total value of $68,748.20. Following the completion of the transaction, the chief executive officer now directly owns 6,317,952 shares in the company, valued at $16,616,213.76. The disclosure for this sale can be found here. Insiders sold a total of 90,423 shares of company stock worth $259,897 in the last three months. 21.20% of the stock is owned by insiders.

Puma Biotechnology Profile

(Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Recommended Stories

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYIGet Rating).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.